The first investment has been made in a company focused on the development of radiopharmaceuticals for precision oncology
VALENCIA, 29 Mar. (EUROPA PRESS) -
Angels --Juan Roig's investment company belonging to Marina de Empresas-- has invested in Biozell, the Valencian joint venture vehicle in biotechnology, pharmaceutical and health companies promoted by Ángela Pérez, vice president of Health in Code and winner of the Rei Jaume I 2022 Award to the Entrepreneur.
Biozell is led by Ángela Pérez and Fernando Ibáñez, General Director of Ethics and CEO of Biohub VLC, the business community for growth and innovation in health and human well-being located in the Marina de València, of which Biozell is the investment arm in companies in the sector.
"Biozell has the dual purpose of supporting the growth of innovative and impactful projects in health and biotechnology, and also giving private investors (business angels) access to such a complex but important sector, hand in hand with experienced people", he declares. Ángela Pérez in a statement.
"Angels invests in numbers one and Ángela Pérez is an entrepreneur and a national benchmark in the field of entrepreneurship and science; hence our investment in Biozell, an initiative that she leads. We are sure that the fund will promote health companies and cutting-edge biotechnology that will offer revolutionary solutions", affirms the general director of Angels, Pepe Peris.
The first investment of the vehicle after the entry of Angels has been made in Ysotope Theranostics, a startup that is being promoted by Lanzadera, an accelerator that is part of Marina de Empresas.
Ysotope is a Deep Tech startup focused on the development, validation and exploitation of radiopharmaceuticals for precision oncology. The company combines drugs with radioactive isotopes, increasing the accuracy and effectiveness of diagnosis and treatment for cancer patients.
The company is led by Carlos Langeber and Natalia Benito, experts in the development of deep tech startups, together with Dr. Raúl Herance, head of Chemistry-Radiochemistry and Preclinical Molecular Imaging at the Vall d'Hebron Research Institute.
"Having the support and investment of Biozell is a privilege that will make it easier for us to validate our technology and will allow us to continue progressing in the development of solutions for a more personalized medicine", emphasizes Carlos Langeber, CEO of the company.